The Clinical Significance and Prognostic Value of HER2 Expression in Bladder Cancer: A Meta-Analysis and a Bioinformatic Analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Sep 20

PMID 34540657

Citations 16

Authors

Kai Gan

Yue Gao

Kuangzheng Liu

Bin Xu

Weijun Qin

Affiliations

Soon will be listed here.

Abstract

Objective: Human Epidermal Growth Factor Receptor 2 (HER2) is highly expressed in multiple malignancies and associated with patients' prognosis, but its role in bladder cancer (BCa) remains elusive. We conducted this meta-analysis to explore the clinical significance and prognostic value of HER2 in BCa.

Methods: PubMed was searched for studies published between January 1, 2000 and January 1, 2020. The odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95%CIs) were used to investigate the relationship between HER2 and BCa pathological features. TCGA was mined for the information regarding as well.

Results: Our study included 14 articles enrolling 1398 people. Expression of HER2 is higher in bladder cancer than in normal tissues. HER2 over-expression is associated with CIS, multifocal tumor, large tumor size, high tumor stage and grade, lymph node metastasis, progression, recurrence and papillary tumor. We could not find a significant association between HER2 expression and survival time in BCa patients.

Conclusions: Our meta and bioinformatic analysis indicated that HER2 expression was related to pathological malignancy and poor prognosis in BCa.

Citing Articles

Clinicopathological characteristics and prognostic significance of HER2 status evaluation in patients with urothelial carcinoma: a retrospective single-center experience in China.

Yang M, Yao Y, Wang K, Qi L, Yang B, Khudadad M Virchows Arch. 2025; .

PMID: 40011272 DOI: 10.1007/s00428-025-04057-x.

Impact of HER2 Expression on the Prognosis of Muscle-Invasive Bladder Cancer Patients Treated with Bladder-Preservation Comprehensive Therapy.

Chen Y, Luo F, Zhang T, Li J Biol Proced Online. 2025; 27(1):2.

PMID: 39871130 PMC: 11771048. DOI: 10.1186/s12575-025-00261-w.

A radiomics-based interpretable machine learning model to predict the HER2 status in bladder cancer: a multicenter study.

Wei Z, Bai X, Xv Y, Chen S, Yin S, Li Y Insights Imaging. 2024; 15(1):262.

PMID: 39466475 PMC: 11519251. DOI: 10.1186/s13244-024-01840-3.

Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas.

Quaquarini E, Grillo F, Gervaso L, Arpa G, Fazio N, Vanoli A Cancers (Basel). 2024; 16(18).

PMID: 39335117 PMC: 11430748. DOI: 10.3390/cancers16183145.

Contrast-enhanced computed tomography-based radiomics nomogram for predicting HER2 status in urothelial bladder carcinoma.

Peng J, Tang Z, Li T, Pan X, Feng L, Long L Front Oncol. 2024; 14:1427122.

PMID: 39206159 PMC: 11349509. DOI: 10.3389/fonc.2024.1427122.

References

Aizawa M, Nagatsuma A, Kitada K, Kuwata T, Fujii S, Kinoshita T . Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer. 2013; 17(1):34-42. DOI: 10.1007/s10120-013-0239-9. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Janjigian Y, Maron S, Chatila W, Millang B, Chavan S, Alterman C . First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020; 21(6):821-831. PMC: 8229851. DOI: 10.1016/S1470-2045(20)30169-8. View

Tsai Y, Shiau A, Chen Y, Tsai H, Tzai T, Wu C . Enhancement of antitumor activity of gammaretrovirus carrying IL-12 gene through genetic modification of envelope targeting HER2 receptor: a promising strategy for bladder cancer therapy. Cancer Gene Ther. 2009; 17(1):37-48. DOI: 10.1038/cgt.2009.41. View

Hayashi T, Seiler R, Oo H, Jager W, Moskalev I, Awrey S . Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. J Urol. 2015; 194(4):1120-31. DOI: 10.1016/j.juro.2015.05.087. View

Olsson H, Fyhr I, Hultman P, Jahnson S . HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder. Scand J Urol Nephrol. 2011; 46(2):102-7. DOI: 10.3109/00365599.2011.637955. View

Lim S, Cho Y, Choi G, Park H, Paick S, Kim W . Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder. J Korean Med Sci. 2015; 30(8):1068-77. PMC: 4520937. DOI: 10.3346/jkms.2015.30.8.1068. View

Nedjadi T, Al-Maghrabi J, Assidi M, Dallol A, Al-Kattabi H, Chaudhary A . Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques. BMC Cancer. 2016; 16:653. PMC: 4990978. DOI: 10.1186/s12885-016-2703-5. View

Zhao J, Xu W, Zhang Z, Song R, Zeng S, Sun Y . Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. Int Urol Nephrol. 2014; 47(1):87-94. DOI: 10.1007/s11255-014-0866-z. View

10.

Olayioye M, Neve R, Lane H, Hynes N . The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19(13):3159-67. PMC: 313958. DOI: 10.1093/emboj/19.13.3159. View

11.

Nagasawa J, Mizokami A, Koshida K, Yoshida S, Naito K, Namiki M . Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int J Urol. 2006; 13(5):587-92. DOI: 10.1111/j.1442-2042.2006.01342.x. View

12.

Kruger S, Weitsch G, Buttner H, Matthiensen A, Bohmer T, Marquardt T . HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer. 2002; 102(5):514-8. DOI: 10.1002/ijc.10731. View

13.

Pietila M, Sahgal P, Peuhu E, Jantti N, Paatero I, Narva E . SORLA regulates endosomal trafficking and oncogenic fitness of HER2. Nat Commun. 2019; 10(1):2340. PMC: 6538630. DOI: 10.1038/s41467-019-10275-0. View

14.

Arya S, Estrela P . Electrochemical ELISA-based platform for bladder cancer protein biomarker detection in urine. Biosens Bioelectron. 2018; 117:620-627. DOI: 10.1016/j.bios.2018.07.003. View

15.

Yarden Y . Biology of HER2 and its importance in breast cancer. Oncology. 2001; 61 Suppl 2:1-13. DOI: 10.1159/000055396. View

16.

Jack S, Madhivanan K, Ramadesikan S, Subramanian S, Edwards 2nd D, Elzey B . A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera. Int J Cancer. 2019; 146(2):449-460. PMC: 10303116. DOI: 10.1002/ijc.32719. View

17.

Latif Z, Watters A, Dunn I, Grigor K, Underwood M, Bartlett J . HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer. 2003; 89(7):1305-9. PMC: 2394319. DOI: 10.1038/sj.bjc.6601245. View

18.

Xylinas E, Rink M, Margulis V, Karakiewicz P, Novara G, Shariat S . Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol. 2012; 61(5):1069-70. DOI: 10.1016/j.eururo.2012.02.042. View

19.

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

20.

Amin M, McKenney J, Paner G, Hansel D, Grignon D, Montironi R . ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. Eur Urol. 2012; 63(1):16-35. DOI: 10.1016/j.eururo.2012.09.063. View